Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

Pharma giant GSK surged to the top of the index as it missed forecasts slightly with its annual results, but raised its ...

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.

London stocks nudged higher in early trade on Wednesday as investors mulled disappointing US tech results and continued to ...

Harvey Jones isn't having much fun playing the GSK share price game. The FTSE 100 pharmaceutical stock must work hard to make ...

The state’s top lawyer accused a British multinational drug company of “deceptive and unfair practices” that endangered lives and exploited American taxpayers.

Wellnex is undertaking a $16 million capital raising ahead of a dual listing on London's AIM exchange, a focal point for European expansion.

Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation of 213 million ...